Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 13/20 | 0.54 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.52 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.49 |
| ▸ | CDK2 | P24941 | 4/20 | 0.49 |
| ▸ | CDK9 | P50750 | 4/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19004306 | 0.89 | GSK3B (0.54) | GSK3BPIK3C3MAPK14ABL1 | |
| SCHEMBL19004621 | 0.89 | GSK3B (0.54) | GSK3BPIK3C3MAPK14ABL1 | |
| SCHEMBL19004456 | 0.86 | GSK3B (0.56) | GSK3BPIK3C3MAPK14ABL1 | |
| SCHEMBL19004593 | 0.86 | MAPK8 (0.55) | GSK3BPIK3C3MAPK14ABL1 | |
| SCHEMBL19004458 | 0.86 | MAPK8 (0.55) | GSK3BPIK3C3MAPK14ABL1 | |
| SCHEMBL18984087 | 0.85 | GSK3B (0.50) | GSK3BPIK3C3CCNT1CCNA2CDK2 | |
| SCHEMBL18984085 | 0.85 | GSK3B (0.50) | GSK3BPIK3C3CCNT1CCNA2CDK2 | |
| SCHEMBL19004309 | 0.81 | ABL1 (0.46) | GSK3BPIK3C3MAPK14ABL1 | |
| SCHEMBL19004754 | 0.81 | ABL1 (0.46) | GSK3BPIK3C3MAPK14ABL1 | |
| SCHEMBL19004572 | 0.80 | ABL1 (0.48) | ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10316049-B2 | Tank-binding kinase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| WO-2017106556-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2017-06-22 | — | — | WO | disclosed |
| US-20170174713-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174713-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | TBKBP1, TNKS1BP1, TNKS | GSK3B 417/4885PIK3C3 522/4885MAPK14 712/4885 |
| US-10316049-B2 | Tank-binding kinase inhibitor compounds | TBKBP1, TNKS1BP1, TNKS | GSK3B 417/4885PIK3C3 522/4885MAPK14 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.